AstraZeneca in Talks to Acquire Bristol Myers Squibb in Near-$400bn Deal

AstraZeneca is in discussions to take over US rival Bristol Myers Squibb, the Financial Times first reported on 3 August 2026, citing unnamed sources. A deal would create a near-$400bn pharmaceutical group — the world's fourth-largest drugmaker by market value. Talks held in recent months may not conclude. AstraZeneca's shares fell over 7% on the news.